uniQure N.V.

QURENASDAQ • USD
ThemeGenomics & Precision Med.›Gene Therapy & Gene Editing
40.25 USD
↗ 0.89 (2.26%)AT CLOSE (11:59 AM EDT)
40.65
↗ 0.40 (1.00%)
POST MARKET (AS OF 07:58 PM EDT)
Post Market
AS OF 07:58 PM EDT
40.65
↗ 0.40 (1.00%)
🔴Market: CLOSED

QURE is currently priced at $40.26. There is a divergence between signals — technical indicators rate "Buy" but underlying fundamentals lean "Sell". Notable factors include a concerning Altman Z-Score in the distress zone, negative Return on Equity and a bullish Golden Cross on the moving averages. Valuation-wise, the stock is priced at a premium — multiples like P/E and EV/EBITDA sit above sector averages.

Technical & fundamental data as of Jul 17, 2026.

Open?$39.12
High?$41.04
Low?$38.20
Prev. Close?$39.36
Volume?958.2K
Avg. Volume?2.6M
VWAP?$40.09
Rel. Volume?0.38x
Bid / Ask
Bid?$34.50 × 100
Ask?$45.64 × 100
Spread?$11.14
Midpoint?$40.07
Valuation & Ratios
Market Cap?2.7B
Shares Out?63.1M
Float?55.9M
Float %?89.4%
P/E Ratio?N/A
P/B Ratio?18.12
EPS?-$3.04
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.
Themes
Healthcare - Genomics & Precision Medicine›Gene Therapy & Gene EditingBiotech - Drug Development›Rare Disease Therapeutics
Employees
221
Market Cap
2.7B
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.uniqure.com
Listed
2014-02-05
Address
PAASHEUVELWEG 25A
AMSTERDAM, 1105 BP
Phone: 1-339-970-7000
Technical OutlookBuy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+2/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?▲ Bullish(+1/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
23
Z-Score?
4
Momentum?
65
Short Sent.?
57
Piotroski F-Score?3/9Weak
Altman Z-Score?0.20Distress
Confidence?62%Moderate
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?20.57%Squeeze Risk
Short Interest?11.5M
Days to Cover?2.6
Free Float55.9M
Avg Daily Volume4.5M
Settlement Date2026-06-30
Financial Health
Current Ratio?10.40Strong
Quick Ratio?10.40Strong
Cash Ratio?2.36Strong
Debt/Equity?0.33Low
ValuationRICHLY VALUEDvs 1 peers + S&P 500
Score
50/100
P/E?
N/A▾
P/B?
Peers
100
S&P
9
18.12HIGH▾
P/S?
Peers
100
S&P
3
149.57HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-15.4CHEAP▾
EV/Sales?
Peers
100
S&P
3
144.59HIGH▾
Returns & Efficiency
ROE?
S&P
3
-139.9%WEAK▾
ROA?
S&P
3
-26.8%WEAK▾
Cash Flow & Enterprise
FCF?$-172559000
Enterprise Value?$2.6B
Fundamentals ratios updated end of day
MarketsMoversWatchlist